Cargando…

Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases

BACKGROUND: The standard of care for colorectal peritoneal carcinomatosis is evolving from chemotherapy to cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with disease limited to the peritoneum. Peritoneal carcinomatosis from colorectal cancer treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ripley, Robert T, Davis, Jeremy L, Kemp, Clinton D, Steinberg, Seth M, Toomey, Mary Ann, Avital, Itzhak
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Study protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889988/ https://www.ncbi.nlm.nih.gov/pubmed/20500867 http://dx.doi.org/10.1186/1745-6215-11-62

Ejemplares similares

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
por: Graf, Wilhelm, et al.
Publicado: (2019)

Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
por: Kleber, Julia, et al.
Publicado: (2023)

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer
por: Wang, Xiao, et al.
Publicado: (2020)

Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups
por: Gomes David, Manuel, et al.
Publicado: (2022)

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes
por: Marrelli, Daniele, et al.
Publicado: (2022)

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
por: Vassos, Nikolaos, et al.
Publicado: (2016)

Treatment of hypermyoglobinemia after CRS + HIPEC for patients with peritoneal carcinomatosis: A retrospective comparative study
por: Liu, Gang, et al.
Publicado: (2017)

In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
por: Said, Ibrahim, et al.
Publicado: (2022)

Cytoreductive Surgery (CRS) and Hyperthermic IntraPeritoneal Chemotherapy (HIPEC): don’t throw the baby out with the bathwater
por: Königsrainer, Alfred, et al.
Publicado: (2018)

Retrospective Analysis of Patients with Signet Ring Subtype of Colorectal Cancer with Peritoneal Metastasis Treated with CRS & HIPEC
por: Prabhu, Aruna, et al.
Publicado: (2020)

Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial
por: Engbersen, M. P., et al.
Publicado: (2021)

Etiological analysis of infection after CRS + HIPEC in patients with PMP
por: Yang, Rui, et al.
Publicado: (2023)

Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
por: Acs, Miklos, et al.
Publicado: (2023)

Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
por: Roth, Lilian, et al.
Publicado: (2023)

CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival
por: Spiliotis, John, et al.
Publicado: (2019)

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
por: Harper, Megan M., et al.
Publicado: (2022)

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review
por: Chen, Vicky, et al.
Publicado: (2022)

The use of Hypotension Prediction Index in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Gangakhedkar, Gauri R., et al.
Publicado: (2022)

Management of Inguinal Involvement of Peritoneal Surface Malignancies by Cytoreduction and HIPEC with Inguinal Perfusion
por: Shachar, Yair, et al.
Publicado: (2015)

Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study
por: Hentzen, Judith E. K. R., et al.
Publicado: (2019)

Patients at Risk for Peritoneal Surface Malignancy of Colorectal Cancer Origin: The Role of Second Look Laparotomy
por: Brücher, Björn LDM, et al.
Publicado: (2013)

Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
por: Manzanedo, Israel, et al.
Publicado: (2023)

Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
por: Zhou, Sicheng, et al.
Publicado: (2021)

First experience with (224)Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)
por: Larsen, Stein Gunnar, et al.
Publicado: (2023)

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
por: Pamela, Kogler, et al.
Publicado: (2018)

Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center
por: Račkauskas, Rokas, et al.
Publicado: (2022)

P.R.O.P.S. — A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Yong, Zachary Zihui, et al.
Publicado: (2019)

Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC: A case report and literature review
por: Ji, Zhong-He, et al.
Publicado: (2019)

Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review
por: Noiret, Barbara, et al.
Publicado: (2022)

Late Recurrence of Pancreatic Solid Pseudopapillary Neoplasm With Peritoneal Carcinomatosis Treated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Case Report
por: Nogueiro, Jorge, et al.
Publicado: (2022)

A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer
por: BATISTA, THALES PAULO, et al.
Publicado: (2022)

The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Tan, Grace Hwei Ching, et al.
Publicado: (2018)

Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Chokshi, Ravi J., et al.
Publicado: (2020)

Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts
por: Herold, Zoltan, et al.
Publicado: (2022)

Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021)

Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Kartik, Akash, et al.
Publicado: (2023)

Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer
por: Simkens, Geert A, et al.
Publicado: (2017)

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
por: Davis, Jeremy L, et al.
Publicado: (2011)

Anesthetic management of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): The importance of hydro-electrolytic and acid-basic control
por: Mendonça, Fabrício Tavares, et al.
Publicado: (2017)

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
por: Zhang, Guyu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hbk8mmrmco2sj1rig8gcegfdh1